Trump Profited From His Giveaway to Big Pharma While Jacking Up Drug Costs
A congressional analysis estimates President Trump increased his pharmaceutical stock holdings from $1.7M in 2024 to $56.2M in 2025, benefiting from policies that raised drug prices. Merck, Johnson & Johnson, AbbVie, Pfizer, and Amgen were among the companies that gained. Merck reported $22.5B in profits in 2025, a 16% increase.
How this was made
The 30-second read
Why it matters
The main tradable implication is sentiment and perceived regulatory/political risk to Medicare pricing for large-cap pharma. However, the article does not announce new CMS actions, court rulings, or company-specific operational changes.
Market read
Traders may reassess political/regulatory overhang for Medicare drug pricing, but the article reads as an analysis rather than a new policy or enforcement event.
What to watch
Investors may discount the claims as political rhetoric unless there is follow-through such as CMS rulemaking, enforcement, or court challenges that specifically target the carveouts.
Background
The article summarizes a Democratic JEC analysis alleging Trump increased personal holdings in Big Pharma while policies allegedly raised drug costs, highlighting Medicare negotiation carveouts in a budget law.
Ticker impact
JEC analysis says Keytruda was temporarily shielded from Medicare price negotiations via a budget carveout, benefiting Merck.
Likely modest sentiment pressure as investors weigh political/regulatory risk to Medicare pricing.
The article is framed as a political critique of policy carveouts; it does not announce new enforcement, guidance, or contract changes for Merck.
The article says J&J had at least one drug that benefited from the Trump-GOP budget law carveouts.
Potential mild downside bias if traders price in future pricing negotiations or political backlash.
No specific J&J drug, revenue impact, or new regulatory action is disclosed beyond the general carveout claim.
The JEC analysis states AbbVie had at least one drug benefiting from the budget carveouts.
Likely limited near-term impact, with sentiment skewing slightly negative on policy risk.
The article provides no AbbVie-specific drug name or quantified effect tied to the carveout.
The article reports Pfizer had at least one drug benefiting from the Trump-GOP budget law carveouts.
Probably small, mostly sentiment-driven move rather than a fundamental repricing.
No Pfizer drug, magnitude, or follow-on policy action is specified.
The JEC analysis says Amgen had at least one drug benefiting from the budget carveouts.
Limited immediate price impact; any effect likely fades unless new policy steps emerge.
The piece does not identify the specific Amgen drug or provide a quantified impact.
The article says the Trump administration entered friendly agreements with pharmaceutical companies in which the president is invested, including Eli Lilly.
Potential mild negative sentiment reaction if markets interpret it as heightened scrutiny risk.
The article references redacted agreement texts but does not disclose new enforceable regulatory outcomes.
Market effects
Reinforces narrative that Medicare pricing negotiations could be politically contested, potentially increasing volatility across large-cap pharma.
Primarily US-focused policy risk narrative; could spill into US-listed pharma sentiment.
Limited direct global impact unless it triggers broader pricing or regulatory scrutiny beyond the US.
Counterpoint
The piece is partisan and centers on a previously enacted budget carveout; absent new regulatory action, near-term fundamentals for these companies may be unchanged.
Key entities
- companyMerck
Keytruda cited as temporarily shielded from Medicare price negotiations under a budget carveout.
- companyJohnson & Johnson
Said to have at least one drug benefiting from the carveouts.
- companyAbbVie
Said to have at least one drug benefiting from the carveouts.
- companyPfizer
Said to have at least one drug benefiting from the carveouts.
- companyAmgen
Said to have at least one drug benefiting from the carveouts.
